An Open-label, Adaptive, Repeat-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long-acting Injection (LAI) in Patients With Schizophrenia
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Iloperidone (Primary) ; Iloperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
- 27 Jun 2023 Status changed from recruiting to completed.
- 01 Jun 2022 Planned End Date changed from 1 Jan 2022 to 1 Sep 2022.
- 01 Jun 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Sep 2022.